3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Observational
1
Sponsor
Conditions
COVID-19
4
Neoplasms
2
Rheumatic Diseases
1
Papillomavirus Infections
1
Nervous System Diseases
1
Lung Neoplasms
1
Hematologic Diseases
1
Interventions
Brentuximab Vedotin
17
fludarabine
9
Cyclophosphamide
9
dacetuzumab
6
Lenalidomide
6
Bortezomib
6
ruxolitinib
5
fludarabine phosphate
5
Rituximab
5
Melphalan
5
Dexamethasone
4
Busulfan
4
lintuzumab
3
Whole-Body Irradiation
3
Mycophenolic Acid
3
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Doxorubicin
3
Calcium Dobesilate
3
Azacitidine
3
vosaroxin
2
spartalizumab
2
ponatinib
2
nilotinib
2
Vincristine
2
Thiotepa
2
Tacrolimus
2
Sugars
2
Stem Cell Transplantation
2
Rifampin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hematologic Diseases
×
COVID-19 Vaccines
×
Clear all
NCT04848493
2025-06-13
VAX4FRAIL
Azienda USL Reggio Emilia - IRCCS
Completed
747 enrolled